Diagnosis and classification of psoriasis

Autoimmunity Reviews

Volumn 13, Issue 4-5, 2014, Pages 490-495

  Raychaudhuri, Smriti K ^a   Maverakis, Emanual ^b   Raychaudhuri, Siba P ^a,b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical spectrum; Diagnosis; Diagnostic criteria; Psoriasis

Indexed keywords

INTERLEUKIN 17; NERVE GROWTH FACTOR; SUBSTANCE P;

AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ERYTHRODERMIC PSORIASIS; GUTTATE PSORIASIS; HISTOPATHOLOGY; HUMAN; KERATINOCYTE; NAIL PSORIASIS; NONHUMAN; ONSET AGE; PATHOGENESIS; PATHOPHYSIOLOGY; PATTERN RECOGNITION; PHENOTYPE; PSORIASIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; REVIEW; SKIN DEFECT; T LYMPHOCYTE;

CLINICAL SPECTRUM; DIAGNOSIS; DIAGNOSTIC CRITERIA; PSORIASIS;

ANIMALS; CHRONIC DISEASE; HUMANS; JOINTS; PHENOTYPE; PSORIASIS; RISK FACTORS; SKIN;

EID: 84896319342     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.01.008     Document Type: Review

References (53)

1. Duffin K.C., Chandran V., Gladman D.D., Krueger G.G., Elder J.T., Rahman P. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol 2008, 35(7):1449-1453.
2. http://www.psoriasis.org/netcommunity/learn.
3. Liu Y., Krueger J.G., Bowcock A.M. Psoriasis: genetic associations and immune system changes. Genes Immun 2007, 8(1):1-12.
4. Chandran V. Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010, 34(3):J314-J321.
5. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296:1735-1741.
6. Raychaudhuri S.P., Gross J. Psoriasis risk factors: role of lifestyle practices. Cutis 2000, 66(5):348-352.
7. Gelfand J.M., Feldman S.R., Stern R.S., Thomas J., Rolstad T., Margolis D.J. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004, 51(5):704-708.
8. Jordan C.T., Cao L., Roberson E.D., Duan S., Helms C.A., Nair R.P., et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet 2012, 90(5):796-808.
9. Jordan C.T., Cao L., Roberson E.D., Pierson K.C., Yang C.F., Joyce C.E., et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 2012, 90(5):784-795.
10. Elder J.T., Bruce A.T., Gudjonsson J.E., Johnston A., Stuart P.E., Tejasvi T., et al. Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 2010, 130(5):1213-1226.
11. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445(7130):866-873.
12. Nickoloff B.J. Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 2006, 12:102-106.
13. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370:263-271.
14. Hertle M.D., Kubler M.D., Leigh I.M., Watt F.M. Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J Clin Invest 1992, 89(6):1892-1901.
15. Iizuka H., Honda H., Ishida-Yamamoto A. Epidermal remodeling in psoriasis (II): a quantitative analysis of the epidermal architecture. J Invest Dermatol 1997, 109(6):806-810.
16. Gottlieb A.B., Lebwohl M., Shirin S., et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000, 43(4). 595-04.
17. Raychaudhuri S.P., Raychaudhuri S.K., Tamura K., Masunaga T., Kubo K., Hanaoka K., et al. FR255734, a humanized, Fc-silent, anti-CD28 antibody improves psoriasis in the SCID mouse-psoriasis xenograft model. J Invest Dermatol 2008, 128(8):1969-1976.
18. Papp K.A., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366(13):1181-1189.
19. Leonardi C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366(13):1190-1199.
20. McInnes I.B., et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014, 73(2):349-356. Epub 2013 Jan 29.
21. Wrone-Smith T., Nickoloff B.J. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996, 98(8):1878-1887.
22. Raychaudhuri S.P., Jiang W.Y., Raychaudhuri S.K. Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 2008, 172(4):961-971.
23. + CTLs as determined by phenotypic analysis. J Cutan Pathol 1998, 25(2):79-88.
24. + T lymphocytes in psoriatic arthritis. J Rheumatol 1999, 26:1117-1124.
25. Laloux L., Voisin M.C., Allain J., Martin N., Kerboull L., Chevalier X., et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001, 60:316-321.
26. Ragaz A., Ackerman A.B. Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol 1979, 1(3):199-214.
27. Murphy M., Kerr P., Grant-Kels J.M. The histopathologic spectrum of psoriasis. Clin Dermatol 2007, 25(6):524-528.
28. Altman E.M., Kamino H. Diagnosis: psoriasis or not? What are the clues?. Semin Cutan Med Surg 1999, 18(1):25-35.
29. Naldi L., Gambini D. The clinical spectrum of psoriasis. Clin Dermatol 2007, 25(6):510-518.
30. Henseler T., Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985, 13:450-456.
31. Pariser D.M., Bagel J., Gelfand J.M., Korman N.J., Ritchlin C.T., Strober B.E., et al. Horn EJ; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007, 143(2):239-242.
32. Raychaudhuri S.P. Gross J.A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol 2000, 17(3):174-178.
33. Farber E.M., Nall L. Epidemiology: natural history and genetics. Psoriasis 1998, 107-157. Dekker, New York. H.H. Roenigk, H.I. Maibach (Eds.).
34. Levine D., Gottlieb A. Evaluation and management of psoriasis: an internist's guide. Med Clin North Am 2009, 93(6):1291-1303.
35. Krishnamurthy K., Walker A., Gropper C.A., Hoffman C. To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of group A streptococcal infection. J Drugs Dermatol 2010, 9(3):241-250.
36. Naldi L., Peli L., Parazzini F., Carrel C.F. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J Am Acad Dermatol 2001, 44(3):433-438.
37. Martin B.A., Chalmers R.J., Telfer N.R. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis?. Arch Dermatol 1996, 132(6):717-718.
38. Sagoo G.S., Tazi-Ahnini R., Barker J.W., Elder J.T., Nair R.P., Samuelsson L., et al. Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol 2004, 122(6):1401-1405.
39. Asumalahti K., Ameen M., Suomela S., Hagforsen E., Michaelsson G., Evans J., et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003, 120(4):627-632.
40. Baker H., Ryan T.J. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 1968, 80(12):771-793.
41. Kawada A., Tezuka T., Nakamizo Y., Kimura H., Nakagawa H., Ohkido M., et al. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci 2003, 31(1):59-64.
42. Rosenberg B.E., Strober B.E. Acrodermatitis continua. Dermatol Online J 2004, 10(3):9.
43. Naldi L., Colombo P., Benedetti Placchesi E., et al. Study design and preliminary results from the pilot phase of the PraKtis study: selfreported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology 2004, 208:38-42.
44. Ohkawara A., Yasuda H., Kobayashi H., Inaba Y., Ogawa H., Hashimoto I., et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol 1996, 76(1):68-71.
45. Viguier M., Allez M., Zagdanski A.M., Bertheau P., de Kerviler E., Rybojad M., et al. High frequency of cholestasis in generalized pustular psoriasis: evidence for neutrophilic involvement of the biliary tract. Hepatology 2004, 40(2):452-458.
46. Oumeish O.Y., Parish J.L. Impetigo herpetiformis. Clin Dermatol 2006, 24(2):101-104.
47. Farber E.M., Nall L. Erythrodermic (exfoliative) psoriasis. Cutis 1993, 51(2):79-82.
48. Balasubramaniam P., Berth-Jones J. Erythroderma: 90% skin failure. Hosp Med 2004, 65(2):100-102.
49. Papp K., Berth-Jones J., Kragballe K., Wozel G., de la Brassinne M. Scalp psoriasis: a reviewof current topical treatment options. J Eur Acad Dermatol Venereol 2007, 21:1151-1160.
50. Janagond A.B., Kanwar A.J. Handa S. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study. J Eur Acad Dermatol Venereol 2013, (Epub ahead of print).
51. Meeuwis K.A., de Hullu J.A., de Jager M.E., Massuger L.F., van de Kerkhof P.C., van Rossum M.M. Genital psoriasis: a questionnaire-based survey on a concealed skin disease in The Netherlands. J Eur Acad Dermatol Venereol 2010, 24(12):1425-1430.
52. Salomon J., Szepietowski J.C., Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg 2003, 7(4):317-321.
53. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol 2008, 26(5):448-459.